ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia

Matthew S. Davids, Othman Al‐Sawaf, M. Porro Lurà et al.|Blood|2021

Cited by 12